Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 18/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27590810 | 1.00 | JAK2 (0.51) | JAK2TP53MAPTHTTKLK7 | |
| SCHEMBL7300480 | 0.81 | KDM4E (0.57) | MAPT | |
| SCHEMBL20887144 | 0.76 | TP53 (0.61) | JAK2TP53MAPTHTTKLK7 | |
| SCHEMBL3077145 | 0.75 | JAK2 (0.68) | JAK2TP53MAPTHTTKLK7 | |
| SCHEMBL31488020 | 0.74 | PARP14 (0.81) | JAK2TP53MAPTHTTKLK7 | |
| SCHEMBL3878367 | 0.74 | PARP14 (0.81) | JAK2TP53MAPTHTTKLK7 | |
| SCHEMBL4652104 | 0.72 | CASP3 (0.55) | TP53MAPTHTTKLK7 | |
| SCHEMBL7308499 | 0.72 | CASP3 (0.55) | TP53MAPTHTTKLK7 | |
| SCHEMBL20887147 | 0.72 | PARP14 (0.82) | JAK2TP53MAPTHTTKLK7 | |
| SCHEMBL9418204 | 0.71 | JAK2 (0.66) | JAK2TP53MAPTHTTKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1923386-A2 | Carbamate caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1268425-B1 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-01-23 | — | — | EP | disclosed |
| CN-100358869-C | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2008-01-02 | — | — | CN | disclosed |
| CN-1994298-A | Carbamate aspartic acid specific cysteine proteinase inhibitors and uses thereof | VERTEX PHARMA (US) | 2007-07-11 | — | — | CN | disclosed |
| US-7074782-B2 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-07-11 | — | — | US | disclosed |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-18 | — | — | US | disclosed |
| US-6689784-B2 | CONTROLLING CELL APOPTOSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-10 | — | — | US | disclosed |
| CN-1422253-A | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2003-06-04 | — | — | CN | disclosed |
| EP-1268425-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-03-07 | — | — | US | disclosed |
| WO-2001072707-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | JAK2 1913/4885TP53 1052/4885MAPT 4419/4885 |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | JAK2 1913/4885TP53 1052/4885MAPT 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.